Cingulate Therapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Cingulate Therapeutics

Access the complete profile.

Cingulate Therapeutics Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	1901 W 47th Place Kansas City, KS 66205

Note: Revenues for privately held companies are statistical evaluations.


Cingulate Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Cingulate Therapeutics's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Cingulate Therapeutics is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Cingulate Therapeutics Annual Revenue and Growth Rate

Cingulate Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$10 - $100 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Cingulate Therapeutics's revenues are gauged from an analysis of company filings.

Cingulate Therapeutics's Income Statement (based on Industry Averages)

Cingulate Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Cingulate Therapeutics is developing and marketing. Cingulate Therapeutics doesn't have any recent trademark applications, indicating Cingulate Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
TYMPREZI Pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder (ADHD)	02/03/2020
TAYLERZA Pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder (ADHD)	02/03/2020
IVOQUS Pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder (ADHD)	02/03/2020

See all trademarks and details in the Full Report.

Market Share of Cingulate Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Cingulate Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Cingulate Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
CEVA U.S. HOLDINGS	Lenexa, KS	100
SPARHAWK LABORATORIES	Lenexa, KS	16
B.F. ASCHER	Lenexa, KS	6
GEORGE KING BIO MEDICAL	Overland Park, KS	3
CINGULATE THERAPEUTICS	Kansas City, KS	2
KC EXTRACTION SERVICES	Lenexa, KS	2

Future Competition: Cingulate Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Cingulate Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)